Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.25 SEK | -8.48% | -22.35% | +36.67% |
Sales 2023 | 5.68M 519K 41.54M | Sales 2024 * | 23.65M 2.16M 173M | Capitalization | 532M 48.6M 3.89B |
---|---|---|---|---|---|
Net income 2023 | -178M -16.27M -1.3B | Net income 2024 * | -155M -14.17M -1.13B | EV / Sales 2023 | 48.9 x |
Net cash position 2023 | 111M 10.17M 814M | Net Debt 2024 * | 25.35M 2.32M 185M | EV / Sales 2024 * | 23.6 x |
P/E ratio 2023 |
-2.19
x | P/E ratio 2024 * |
-2.78
x | Employees | 31 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 57.48% |
Latest transcript on IRLAB Therapeutics AB
1 day | -8.48% | ||
1 week | -22.35% | ||
Current month | -34.29% | ||
1 month | -36.73% | ||
3 months | -29.31% | ||
6 months | +48.55% | ||
Current year | +36.67% |
Managers | Title | Age | Since |
---|---|---|---|
Clas Sonesson
FOU | Founder | 63 | 31/12/12 |
Chief Executive Officer | 71 | 05/05/17 | |
Nicholas Waters
FOU | Founder | 62 | 31/12/12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jan Anders Vedin
BRD | Director/Board Member | 82 | 31/12/15 |
Rein Piir
BRD | Director/Board Member | 66 | 31/12/15 |
Chairman | 66 | 31/03/19 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 10.25 | -8.48% | 53,070 |
25/04/24 | 11.2 | +6.16% | 40,046 |
24/04/24 | 10.55 | -8.26% | 107,324 |
23/04/24 | 11.5 | -7.26% | 37,691 |
22/04/24 | 12.4 | -6.06% | 58,486 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 04:29 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.67% | 48.49M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- IRLAB A Stock